Mar 18, 2014
HIV and Hepatitis
CROI 2014: Lopinavir or Lamivudine Equally Protective Against HIV During Breast-feeding
Peri-exposure prophylaxis using either lopinavir/ritonavir and lamivudine proved equally protective as infant prophylaxis against HIV infection during 12 months of breast-feeding, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections this month in Boston.
Deep Sequencing Reveals Minor Protease Resistance Mutations in...
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.
Efavirenz-based ART matches lopinavir/ritonavir for perinatal HIV treatment
Pregnant women taking efavirenz-based antiretroviral therapy had significantly better virologic outcomes at the time of delivery compared to those taking lopinavir/ritonavir in a randomised study in rural Uganda, Dr Deborah Cohan, reporting on behalf of the PROMOTE study team, told attendees at the 21st Conference on Retroviruses and Opportunistic ... (more)
Lopinavir/ritonavir or 3TC PrEP equally protective against infant HIV infection during breastfeeding
Lopinavir/ritonavir or lamivudine proved equally protective as infant prophylaxis against HIV infection during 12 months of breastfeeding, Dr. Chipepo Kankasa presenting on behalf of the ANRS 12174 trial told participants at the 21st Conference on Retroviruses and Opportunistic Infections last week in Boston.
Malnutrition decreases effectiveness of HIV treatment in pregnant African women
In Uganda the prescription of three antiretroviral drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates.